Teligent Inc. (NASDAQ:TLGT)’s share price rose 4.1% during mid-day trading on Wednesday . The company traded as high as $8.43 and last traded at $8.41, with a volume of 147,690 shares traded. The stock had previously closed at $8.08.

A number of equities analysts have weighed in on the company. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Teligent in a research note on Tuesday, April 26th. Zacks Investment Research upgraded Teligent from a “sell” rating to a “hold” rating in a research note on Saturday, April 30th. Raymond James Financial Inc. assumed coverage on Teligent in a research note on Wednesday, June 22nd. They set a “strong-buy” rating and a $11.00 price objective for the company. TheStreet upgraded Teligent from a “sell” rating to a “hold” rating in a research note on Thursday, June 23rd. Finally, JMP Securities assumed coverage on Teligent in a research note on Wednesday, June 29th. They set a “hold” rating for the company. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Teligent currently has an average rating of “Buy” and an average price target of $9.81.

The firm’s 50-day moving average price is $6.99 and its 200-day moving average price is $6.19. The company’s market capitalization is $445.17 million.

Teligent (NASDAQ:TLGT) last issued its earnings results on Thursday, April 28th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.05. The company earned $15.70 million during the quarter, compared to analysts’ expectations of $14.33 million. The firm’s revenue was up 46.7% compared to the same quarter last year. Equities research analysts expect that Teligent Inc. will post $0.01 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Teligent stock. Russell Frank Co bought a new position in shares of Teligent Inc. (NASDAQ:TLGT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 410,606 shares of the company’s stock, valued at approximately $3,605,000. Russell Frank Co owned about 0.78% of Teligent as of its most recent SEC filing.

Teligent, Inc, formerly IGI Laboratories, Inc, is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.